180 related articles for article (PubMed ID: 37564989)
1. Editorial: Neuroendocrine tumors: the road to precision medicine.
La Salvia A; Giuffrida D; Modica R
Front Endocrinol (Lausanne); 2023; 14():1253319. PubMed ID: 37564989
[No Abstract] [Full Text] [Related]
2. Clinical implications of lung neuroendocrine neoplasm classification.
Metovic J; Barella M; Harari S; Pattini L; Albini A; Sonzogni A; Veronesi G; Papotti M; Pelosi G
Expert Rev Anticancer Ther; 2021 Apr; 21(4):377-387. PubMed ID: 33306420
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Neuroendocrine Tumors to Parotid Gland: Where Do They Come From?
Braun A; Cheng L; Reddy S; Gattuso P; Yan L
Int J Surg Pathol; 2023 Apr; 31(2):167-174. PubMed ID: 35466730
[No Abstract] [Full Text] [Related]
4. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.
Boilève A; Faron M; Fodil-Cherif S; Bayle A; Lamartina L; Planchard D; Tselikas L; Kanaan C; Scoazec JY; Ducreux M; Italiano A; Baudin E; Hadoux J
Eur J Cancer; 2023 Jun; 186():122-132. PubMed ID: 37062210
[TBL] [Abstract][Full Text] [Related]
5. Insulinoma-associated 1: A sensitive marker of neuroendocrine differentiation in cutaneous and metastatic neuroendocrine tumors.
Cassarino DS
J Cutan Pathol; 2021 Jan; 48(1):8-10. PubMed ID: 33067832
[No Abstract] [Full Text] [Related]
6. Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms.
Dam G; Grønbæk H; Sundlöv A; Botling J; Sundin A; Petersen RH; Welin S; Evensen ET; Sorbye H; Tabaksblat E; Arveschoug AK; Mortensen J; Kjaer A; Knigge U; Tiensuu Janson E; Langer SW
Acta Oncol; 2023 May; 62(5):431-437. PubMed ID: 37194281
[TBL] [Abstract][Full Text] [Related]
7. Immunosensitivity and specificity of insulinoma-associated protein 1 (INSM1) for neuroendocrine neoplasms of the uterine cervix.
Kuji S; Endo A; Kubota M; Uekawa A; Kawakami F; Mikami Y; Koike J; Suzuki N
J Gynecol Oncol; 2023 Jan; 34(1):e1. PubMed ID: 36245222
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine neoplasms in the breast oncology field: dilemmas of nature and morphology.
Kawasaki T; Tashima T; Enomoto A; Ichikawa J; Nagai H; Muramatsu C; Nakamura Y; Kaira K
Front Endocrinol (Lausanne); 2023; 14():1216424. PubMed ID: 38027104
[No Abstract] [Full Text] [Related]
9. A new immunohistochemical marker, insulinoma-associated protein 1 (INSM1), for Merkel cell carcinoma: Evaluation of 24 cases.
Leblebici C; Yeni B; Savli TC; Aydın Ö; Güneş P; Cinel L; Şimşek BÇ; Yıldız P; Tuncel D; Kayahan S
Ann Diagn Pathol; 2019 Jun; 40():53-58. PubMed ID: 31031215
[TBL] [Abstract][Full Text] [Related]
10. 177Lu-DOTATATE versus 177Lu-EDTMP versus cocktail/sequential therapy in bone-confined painful metastatic disease in medullary carcinoma of the thyroid and neuroendocrine tumour: can semiquantitative comparison of 68Ga-DOTATATE and 18F-fluoride PET-CT aid in personalized treatment decision making in selecting the best therapeutic option?
Basu S; Ranade R; Thapa P
Nucl Med Commun; 2016 Jan; 37(1):100-2. PubMed ID: 26587985
[No Abstract] [Full Text] [Related]
11. [Expression of CD200 and INSM1 in gastrointestinal and pancreatic neuroendocrine neoplasms and its diagnostic values].
Cao Z; Cen HB; Wei JG; Qin LZ; Liao W; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2021 Oct; 50(10):1134-1138. PubMed ID: 34619866
[No Abstract] [Full Text] [Related]
12. Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas.
Kervarrec T; Tallet A; Miquelestorena-Standley E; Houben R; Schrama D; Gambichler T; Berthon P; Le Corre Y; Hainaut-Wierzbicka E; Aubin F; Bens G; Tabareau-Delalande F; Beneton N; Fromont G; Arbion F; Leteurtre E; Touzé A; Samimi M; Guyétant S
Mod Pathol; 2019 Apr; 32(4):499-510. PubMed ID: 30349028
[TBL] [Abstract][Full Text] [Related]
13. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
Bellizzi AM
Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine Merkel cell nodal carcinoma of unknown primary site: management and outcomes of a rare entity.
Kotteas EA; Pavlidis N
Crit Rev Oncol Hematol; 2015 Apr; 94(1):116-21. PubMed ID: 25573607
[TBL] [Abstract][Full Text] [Related]
15. Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.
Refardt J; Hofland J; Kwadwo A; Nicolas GP; Rottenburger C; Fani M; Wild D; Christ E
Rev Endocr Metab Disord; 2021 Sep; 22(3):581-594. PubMed ID: 32495250
[TBL] [Abstract][Full Text] [Related]
16. Incidence and prevalence of neuroendocrine neoplasms in Norway 1993-2021.
Thiis-Evensen E; Boyar Cetinkaya R
J Neuroendocrinol; 2023 Apr; 35(4):e13264. PubMed ID: 36988112
[TBL] [Abstract][Full Text] [Related]
17. Primary neuroendocrine carcinoma of the vagina with Merkel cell carcinoma phenotype.
Coleman NM; Smith-Zagone MJ; Tanyi J; Anderson ML; Coleman RL; Dyson SW; Reed JA
Am J Surg Pathol; 2006 Mar; 30(3):405-10. PubMed ID: 16538063
[TBL] [Abstract][Full Text] [Related]
18. Treatment landscape of advanced high-grade neuroendocrine neoplasms.
Alheraki SZ; Almquist DR; Starr JS; Halfdanarson TR; Sonbol MB
Clin Adv Hematol Oncol; 2023 Jan; 21(1):16-26. PubMed ID: 36638352
[TBL] [Abstract][Full Text] [Related]
19. Skin Metastases of Gastrointestinal Neuroendocrine Tumors - Literature Review.
Molasy B; Zemła P; Kuśnierz K
Pol Przegl Chir; 2022 Mar; 94(5):60-65. PubMed ID: 36169582
[TBL] [Abstract][Full Text] [Related]
20. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O
Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
